991O First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors von Sanborn, R.E., Patel, M.R., Rodon, J., Thein, K.Z., Friedman, C., Levitz, D., Ngirailemesang, I., Goodman, A., Agarwal, P., Friedman, E., Danaee, H., Robell, K., Jaeger, S., Sun, H., Debanne, E., Dunn, J., Wright, E., Reilly, T., Luke, J.J., Redig, A.

Volltext

Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study von Behl, Deepti, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Farrington, Laura Catherine, Crysler, Oxana V., Dib, Elie G., Duvivier, Herbert Leon, Hall, Michael J., Salmon, John Stuart, Alese, Olatunji B., Marr, Alissa S., Ngirailemesang, Isa, Polavaram, Latha, Thota, Ramya, Yang, Eddy Shih-Hsin, O'Lone, Raegan, Grantham, Gina N., Halabi, Susan, Schilsky, Richard L.

Volltext

Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study von Srkalovic, Gordan, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Nazemzadeh, Reza, Cannon, Timothy Lewis, Duvivier, Herbert Leon, Yost, Kathleen J, Pakkala, Suchita, Alva, Ajjai Shivaram, Behl, Deepti, Gold, Philip Jordan, Calfa, Carmen Julia, Ngirailemesang, Melissa, Powell, Steven Francis, O'Lone, Raegan, Grantham, Gina N., Halabi, Susan, Schilsky, Richard L.

Volltext